Abstract
The Bronx was an early epicenter of the COVID-19 pandemic in the USA. We conducted temporal genomic surveillance of SARS-CoV-2 genomes across the Bronx from March-October 2020. Although the local structure of SARS-CoV-2 lineages mirrored those of New York City and New York State, temporal sampling revealed a dynamic and changing landscape of SARS-CoV-2 genomic diversity. Mapping the trajectories of variants, we found that while some have become ‘endemic’ to the Bronx, other, novel variants rose in prevalence in the late summer/early fall. Geographically resolved genomes enabled us to distinguish between a case of reinfection and a case of persistent infection. We propose that limited, targeted, temporal genomic surveillance has clinical and epidemiological utility in managing the ongoing COVID pandemic.
Significance The ongoing emergence of novel SARS-CoV-2 variants has highlighted the need for continual genomic surveillance in order to track their spread and limit introductions into new areas. An understanding of circulating viral strains also provides a powerful tool that can be used to make clinical inferences. Here, we employ temporally and geographically resolved sequencing of SARS-CoV-2 samples in order to describe the local landscape of viral variants in the Bronx and to differentiate between cases of re-infection and persistent infection. We propose that local and targeted sequencing of viral isolates is an underutilized approach for managing the COVID pandemic.
Competing Interest Statement
KC is a member of the scientific advisory boards of Integrum Scientific, LLC and the Pandemic Security Initiative of Celdara Medical, LLC..
Funding Statement
L.K. is supported in part by a Peer Reviewed Cancer Research Program Career Development Award from the United States Department of Defense (CA171019). S.K. is supported by the Einstein Medical Scientist Training Program (2T32GM007288-45) and by a National Institutes of Health T32 Fellowship in Geographic Medicine and Emerging Infectious Diseases (2T32AI070117-13). K.S. is supported by a National Institutes of Health F30 Fellowship (F30CA200411) and T32 Fellowship (T32GM007288).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by the Institutional Review Board of Albert Einstein College of Medicine under IRB number 2016-6137.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All sequences generated in this study have been made publicly available through the GISAID hCoV-19 sequence database. The source code used for sequencing, analysis, and figure generation, is hosted on Github at https://github.com/kellylab/genomic-surveillance-of-the-bronx.
https://github.com/kellylab/genomic-surveillance-of-the-bronx
